Arbutus Biopharma (ABUS) Operating Margin (2013 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Operating Margin of 94.3% for Q1 2026, up 155116.0% year-on-year from N/an in Q1 2025, and up 118.73% on a QoQ basis from 503.33% in Q4 2025.
Arbutus Biopharma (ABUS) Operating Margin (2013 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Operating Margin for 14 consecutive years, with 94.3% the latest figure, recorded in Q1 2026.
- Quarterly Operating Margin rose 155116.0% year-over-year to 94.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81.72% (up 137260.0% YoY) and the FY2025 annual result came in at 270.96%, up 96577.0% from the prior year.
- Operating Margin improved to 94.3% in Q1 2026 per ABUS's latest filing, from 503.33% in the prior quarter.
- Over the last five years, Operating Margin for ABUS reached as high as 94.3% in Q1 2026 and fell as low as 1636.86% in Q3 2025.
- A 5-year average of 671.9% and a median of 462.82% in 2023 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2024 — Operating Margin slumped 113838 bps — and 2026, when it soared 155116 bps.
- Year by year, Operating Margin stood at 361.28% in 2022, then tumbled by 168 bps to 967.23% in 2023, then rose by 8 bps to 885.2% in 2024, then surged by 43 bps to 503.33% in 2025, then soared by 119 bps to 94.3% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 94.3%, 503.33%, and 1636.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 94.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.30% |
| Dec 31, 2025 | -503.33% |
| Sep 30, 2025 | -1,636.86% |
| Jun 30, 2025 | 13.86% |
| Mar 31, 2025 | -1,456.86% |
| Dec 31, 2024 | -885.20% |
| Sep 30, 2024 | -1,601.19% |
| Jun 30, 2024 | -1,250.46% |
| Mar 31, 2024 | -1,263.90% |
| Dec 31, 2023 | -967.23% |
| Sep 30, 2023 | -462.82% |
| Jun 30, 2023 | -395.29% |
| Mar 31, 2023 | -260.40% |
| Dec 31, 2022 | -361.28% |
| Sep 30, 2022 | -299.24% |
| Jun 30, 2022 | -99.07% |
| Mar 31, 2022 | -87.23% |
| Dec 31, 2021 | -648.66% |
| Sep 30, 2021 | -551.14% |
| Jun 30, 2021 | -800.43% |